As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.

The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.

For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit (angela.steinbach@uk-koeln.de or vassiliki.dimitriou@uk-koeln.de).

ReCovER

AcronymISRCTNEudraCTNCT (clinicaltrials.gov)DRKS

Registry for Clinical Presentation and Management of Patients with Coronavirus Disease 2019 in the Emergency Room

Status: Active

Purpose / Objectives

Primary Outcome

  • Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.

Secondary Outcomes

  • Determination of the course of the disease and the state at which patients present to the ED
  • Identification of the ratio of patients with mild or moderate to severe disease
  • Comparison of diagnostic data with regard to the diagnosis of COVID-19
  • Comparison of different approaches to hypoxemia of patients and types of ventilatory support

  • Comparison of methods of risk stratification and allocation of hospital capacities

  • Description of diagnostic (including all results) and therapeutic management (including specific therapy for COVID-19) during hospitalization

  • Description of the clinical course of patients including dates of discharge or death

  • To develop clinical screening and diagnostic approaches

  • To determine baseline prognostic factors to identify patients at high risk

Diagnosis

Patient attributes

Inclusion criteria

  • Clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED

Exclusion criteria

  • None

Trial design

  • Phase IV
  • Multicenter
  • Retrospective
  • Two-arm

Intervention

No intervention.

Documents (password protected)

Responsibilities in overall trial

National Coordinating Investigator

PD Dr. med. Volker Burst

Data management

Studienzentrum Med II